Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Four years after launching a remote-controlled robotic laboratory in San Diego, Eli Lilly is shipping the operation overseas.

Eli Lilly has again upped the ante in scaling up its manufacturing footprint, this time revealing an investment totaling $1.8 billion to expand production capacity at two plants in Ireland. | Eli ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Many of the industry’s glitzy new buildings are showcasing impressive artwork by artists dealing with homelessness or living ...

As the company continues to push for GLP-1 market share, it has tapped an internal veteran with recent experience managing research and development finance.

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Eli Lilly exhibits robust revenue growth, with Q2 revenue surging by 36%, driven by new products contributing nearly $3.5 billion compared to the same period last year (David Ricks, Chair and CEO).